Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: A single center prospective study
Journal of Hepato-Biliary-Pancreatic Sciences · 2025
DOI: 10.1002/jhbp.12121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2025. Verfasst von Takashi Ito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Liver Transplantation, Living Donors, Bile Duct Neoplasms, Klatskin Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
The prognosis for unresectable perihilar cholangiocarcinoma (phCCA) is extremely poor. Liver transplantation in combination with neoadjuvant chemoradiation therapy has become the treatment of choice for unresectable phCCA in the USA. In 2018, we launched a prospective study to evaluate the safety and efficacy of living donor liver transplantation (LDLT) for unresectable phCCA.
Methods
A total of 10 patients were enrolled in this study between 2018 and 2024. Finally, five patients with unresectable phCCA underwent LDLT after neoadjuvant chemotherapy, radiation, and staging laparotomy, while the other five patients dropped out of the protocol.
Results
The median follow‐up period was 23.7 months. The overall survival rate for the five patients who underwent LDLT was 100% after one year. Hepatic artery thrombosis and delayed gastric emptying occurred in two and three cases, respectively. The histological efficacy of preoperative treatment was grade IIb and III, according to the Evans classification, in all five patients. All surgical margins and dissected lymph nodes were negative. Four patients were alive with no evidence of disease recurrence while one patient had recurrence 10 months after LDLT.
Conclusions
LDLT is feasible and may be a last‐resort treatment option for unresectable phCCA, although the long‐term outcomes need to be carefully monitored. Clinical trial register and clinical registration number The UMIN registration number for this study is 000033348.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Gastroenterological Surgery and Oncology, Medical Research Institute, Kitano Hospital, Osaka, Japan.
- Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Kyoto, Japan.
ORCID-Profile: Takashi Ito, Kojiro Taura, Ken Fukumitsu, Satoshi Ogiso, Yoichiro Uchida, Takamichi Ishii, Etsuro Hatano
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ito, T., Taura, K., Fukumitsu, K., Okumura, S., Ogiso, S., Anazawa, T., Nagai, K., Uchida, Y., Ishii, T., & Hatano, E. (2025). Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: A single center prospective study. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.12121
Vancouver
Ito T, Taura K, Fukumitsu K, Okumura S, Ogiso S, Anazawa T, et al. Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: A single center prospective study. Journal of Hepato-Biliary-Pancreatic Sciences. 2025. doi:10.1002/jhbp.12121
BibTeX
@article{Ito2025,
author = {Ito, Takashi and Taura, Kojiro and Fukumitsu, Ken and Okumura, Shinya and Ogiso, Satoshi and Anazawa, Takayuki and Nagai, Kazuyuki and Uchida, Yoichiro and Ishii, Takamichi and Hatano, Etsuro},
title = {Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: A single center prospective study},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
doi = {10.1002/jhbp.12121}
}
EUVIMED